Moreover, usage of AS-1411, an oligodeoxynucleotide aptamer specifically targeting NCL that reached phase I and II clinical trials for cancer treatment including AML, displayed similar effects as NCL knock-down [12,31,32]. The gene discussed is NUCLEOLIN; the disease is acute myeloid leukemia.